Expanded Access Program of AMTAGVI that is Out of Specification for Commercial Release

Disease Sites:

Melanoma

Staging:

N/A

Age Group:

Adults

Therapies:

Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics

Drugs:

AMTAGVI, Cyclophosphamide, Fludarabine, IL-2, Mesna

Principal Investigator(s):

Johnson, Douglas

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

09-18-2025

Trial Type:

Treatment

Protocol ID:

VICCMEL24579

National Clinical Trial ID:

NCT05398640

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available